Pharming Group (NASDAQ:PHAR – Free Report) had its price objective increased by Oppenheimer from $30.00 to $39.00 in a report released on Friday morning,Benzinga reports. They currently have an outperform rating on the stock.
PHAR has been the topic of several other research reports. HC Wainwright restated a “buy” rating and set a $37.00 price target on shares of Pharming Group in a research report on Friday. Jefferies Financial Group initiated coverage on Pharming Group in a research note on Monday, December 9th. They issued a “buy” rating and a $14.00 price target for the company.
Get Our Latest Research Report on PHAR
Pharming Group Trading Up 0.3 %
Pharming Group (NASDAQ:PHAR – Get Free Report) last issued its quarterly earnings data on Thursday, March 13th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.02). The company had revenue of $92.70 million during the quarter, compared to analyst estimates of $76.67 million. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. Equities research analysts predict that Pharming Group will post -0.2 earnings per share for the current year.
Institutional Investors Weigh In On Pharming Group
An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its stake in Pharming Group (NASDAQ:PHAR – Free Report) by 16.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 47,997 shares of the company’s stock after purchasing an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 as of its most recent SEC filing. Institutional investors and hedge funds own 0.03% of the company’s stock.
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Further Reading
- Five stocks we like better than Pharming Group
- Investing in Commodities: What Are They? How to Invest in Them
- How to Build the Ultimate Everything ETF Portfolio
- The Role Economic Reports Play in a Successful Investment Strategy
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.